Skip to content

The preventive effect of bisphosphonate to urolithiasis

The preventive effect of bisphosphonate to urolithiasis - The preventive effect of bisphosphonate to urolithiasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002979
Enrollment
120
Registered
2010-01-05
Start date
2009-05-01
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urolithiasis

Interventions

Sponsors

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients' stone include no calcium. Patients with treatment for osteoporosis (vitamine D or elcitonin). Patiens who were administrated bisphosphonate between the past three years. Patients with stricture of the esophagus or gullet achalasia. Patients cannot keep a standing position or seat digit at the time of taking more than 30 minutes. A pregnant woman or the case of the woman with possibility becoming pregnant. Patients that takes hormone replacement therapy. Patients that takes an adrenocorticosteroid drug. Patients that takes a citric acid drug. Patients that takes the anti-malignant tumor agent. Patients that it is judged that medication is not appropriate.

Design outcomes

Primary

MeasureTime frame
Recurrence of urolithiasis

Secondary

MeasureTime frame
Risk-parameter of urolithiasis

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026